Ruboxistaurin for the treatment of diabetic peripheral neuropathy: A systematic review of randomized clinical trials

Dipika Bansal, Yogesh Badhan, Kapil Gudala, Fabrizio Schifano

    Research output: Contribution to journalArticlepeer-review

    36 Citations (Scopus)


    Background: Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus. Protein kinase C (PKC) inhibitor's has been thought to be a potential disease modifying drug's in DPN as it slows or reverse neuropathy's progression. To assesses the efficacy and safety of ruboxistaurin on the progression of symptoms, signs, or functional disability in DPN. Methods: A systematic review of the literature databases like PubMed, ProQuest, EBSCO, EMBASE, and Cochrane Central was performed up to August 2012. We included randomized controlled trials (RCTs) comparing PKC inhibitor ruboxistaurin (RBX) with control and lasting at least 6 months. Our primary outcome measure was change in neurological examination, measured by neurological total symptom score (NTSS) and vibration detection threshold (VDT). Secondary outcome measures were total quality of life (QoL), skin microvascular blood flow and others. Results: Six RCTs were included in review. Change in neurological function assessed by NTSS was reported in six studies, out of which significant difference between the RBX and placebo group seen in four studies favouring treatment group while remaining two studies reported no significant difference. VDT was assessed in only one study in which no significant difference seen between RBX and placebo group. Two studies reported significant improvement in QoL data. Safety data was reported in only two studies in which none of side effect was related to RBX. Conclusion: RBX had effects on DPN in some studies, but the evidence is not enough for meta-analysis and firm conclusion.

    Original languageEnglish
    Pages (from-to)375-384
    Number of pages10
    JournalDiabetes & Metabolism Journal
    Issue number5
    Publication statusPublished - 1 Oct 2013


    • Diabetic peripheral neuropathy
    • Protein kinase C inhibitor
    • Ruboxistaurin


    Dive into the research topics of 'Ruboxistaurin for the treatment of diabetic peripheral neuropathy: A systematic review of randomized clinical trials'. Together they form a unique fingerprint.

    Cite this